

Current and future management of patients with EGFRm advanced NSCLC progressing on third-generation EGFR-TKIs

Monday 8 August 2022 | 13:30–14:30 (CEST)

Hall C7, Messe Wien Exhibition & Congress Center, Vienna, Austria

Lunch boxes and refreshments will be available for all attendees

Faculty



Pasi Jänne (Chair)
Dana-Farber Cancer
Institute, USA



Myung-Ju Ahn
Sungkyunkwan University School
of Medicine, South Korea



S. Michelle Shiller
PathGroup, USA

Agenda

Welcome and introduction

Pasi Jänne (Chair)

Current management of patients progressing on third-generation EGFR-TKIs

Myung-Ju Ahn

Evolving treatment landscape for patients with EGFRm advanced NSCLC and c-MET-driven resistance to third-generation EGFR-TKIs

Pasi Jänne

Optimal biomarker testing to identify patients with MET-driven resistance

S. Michelle Shiller

Panel discussion and live Q&A

Moderated by Pasi Jänne (Chair)